Clinical trials: CVD - Cardiovascular Disease
Tricuspid Regurgitation
A Feasibility Study of the CroíValve DUO System for Tricuspid Regurgitation
This study is prospective, multicentre, non-randomized single-arm early feasibility study to evaluate the safety and performance of the CroíValve DUO Transcatheter Tricuspid Coaptation Valve System in patients with severe…
- Trial name
- TANDEM I (NCT05296148)
- Testing
- Transcatheter Tricuspid Valve Implantation
- Where
- 3 sites in Poland
- Volunteers
- 10 people
- Sponsor
- CroiValve Limited
Acute Ischemic Stroke
MRI-based Artificial Intelligence Software (NNS-SOT) for Onset Time Estimation in Lesion With Acute Ischemic Stroke
This study evaluates the efficacy of investigational device named Stroke Onset Time Artificial Intelligence(AI) (Model name:NNS-SOT).
- Trial name
- NCT06160726
- Where
- South Korea
- Volunteers
- 474 people
- Sponsor
- Nunaps Inc
Stroke
Rehabilitation of the Stroke Hand at Home
The purpose of this research is to evaluate a therapy delivery system for stroke patients that provide accessible, affordable stroke care.
- Trial name
- HAAPI (NCT01144715)
- Testing
- Hand Mentor (TM) robotic stroke therapy device, Home Therapy Program
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Kinetic Muscles
Retinal Vein Occlusion
Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea
This study is a Post-Market Surveillance study in Korea to evaluate the safety and efficacy of dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant used to treat Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or…
- Trial name
- NCT01976650
- Testing
- dexamethasone 700 ㎍ intravitreal implant
- Where
- South Korea
- Volunteers
- 724 people
- Sponsor
- Allergan
Dyslipidemia
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
The primary clinical hypothesis is that long-term exposure of evolocumab will be safe and well tolerated in subjects with clinically evident atherosclerotic cardiovascular disease (CVD).
- Trial name
- FOURIER OLE (NCT02867813)
- Testing
- Evolocumab
- Where
- 198 sites in United States, Czechia and 5 more
- Volunteers
- 5,035 people
- Sponsor
- Amgen
Aortic Valve Stenosis
Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial
The purpose of this study is to evaluate the safety and performance of the HLT System in patients with severe aortic stenosis who present at High Risk for aortic valve replacement surgery.
- Trial name
- RADIANT (NCT02799823)
- Testing
- HLT Transcatheter Aortic Valve System
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- HLT Inc.
Hypertension
Rheos Feasibility Trial
The Rheos Feasibility Trial is designed to assess safety, device performance, and protocol parameters of the CVRx Rheos Baroreflex Therapy in patients with severe hypertension that are refractory to full drug therapy.
- Trial name
- NCT01077180
- Testing
- Implantation of the Rheos System, Standard of care medical management
- Volunteers
- 16 people
- Sponsor
- CVRx, Inc.
Heart Failure
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
Analysis of cell and protein deposits on the Impella Heart Pump.
- Trial name
- NCT06765226
- Where
- 7 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Abiomed Inc.
Arterial Occlusive Diseases
The Study to Treat Superficial Femoral Artery Occlusions.
The main objective of this study is to assess the performance of the Cordis SMART™ nitinol self-expandable stent for the treatment of superficial femoral artery (SFA) occlusions in comparison with balloon angioplasty only as…
- Trial name
- SUPER UK (NCT00232843)
- Testing
- stent, angioplasty
- Where
- 2 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cordis US Corp.
Arrythmia, Implantable Cardioverter Defibrillator
Clinical and Device Functional Assessment of Real World ICD Patients
The primary requirement of the implantable cardioverter defibrillator (ICD) is to preserve life by terminating life-threatening arrhythmias (VT/VF).
- Trial name
- CARAT (NCT02341768)
- Testing
- ICD
- Where
- 102 sites in Austria, Canada and 10 more
- Volunteers
- 2,056 people
- Sponsor
- MicroPort CRM
Dementia, Alzheimer Disease
The BRAIN App (Phase 2 SBIR)
There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S.
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT06298474
- Testing
- The BRAIN App
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Hopeful Aging
Peripheral Arterial Disease, Intermittent Claudication
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
The ENTRAP Study is a prospective, multi-center, non-randomized, single-arm, study with follow-up to 30 days to determine the acute safety, acute device performance and clinical performance of the Vanguard IEP Peripheral Balloon…
- Conditions
- Peripheral Arterial Disease, Intermittent Claudication, Atherosclerosis of Femoral Artery
- Trial name
- ENTRAP (NCT03271710)
- Testing
- peripheral balloon angioplasty
- Where
- 9 sites in Belgium, Germany
- Volunteers
- 113 people
- Sponsor
- Contego Medical, Inc.
Aortic Aneurysm, Thoracic
Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
The purpose of this post-approval study is to evaluate the long-term performance of the GORE TAG® Thoracic Endoprosthesis (TAG device) in the primary treatment of descending thoracic aortic (DTA) aneurysms
- Trial name
- NCT00590759
- Testing
- GORE TAG® Thoracic Endoprosthesis
- Where
- 25 sites in United States
- Volunteers
- 150 people
- Sponsor
- W.L.Gore & Associates
Mitral Regurgitation
Treatment of Mitral Regurgitation Using a Minimally Invasive Approach With the HARPOON Device.
To evaluate the long-term safety and performance of the HARPOON™ MVRS for use in patients presenting with severe degenerative mitral regurgitation due to posterior leaflet prolapse in the post-market phase.
- Trial name
- ASCEND (NCT04382612)
- Testing
- HARPOON Beating Heart Mitral Valve Repair System (MVRS)
- Where
- 10 sites in Austria, Germany and 2 more
- Volunteers
- 42 people
- Sponsor
- Edwards Lifesciences
Healthy
Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.
This study will assess the bioavailability of aliskiren and valsartan as a single tablet compared to the same doses of the two drugs given as two separate tablets in healthy subjects.
- Trial name
- NCT00416728
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis
Coronary Artery Disease
Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent
The purpose of this study is to compare the one-time application of Paclitaxel from SeQuent Please (Paclitaxel-coated Balloon Catheter) after using the Coroflex Blue (Cobalt Chromium Stent) with the slow releasing of small dose…
- Trial name
- NCT01166711
- Testing
- Coroflex Blue (BMS) followed by SeQuent Please (DEB), Coroflex Please (DES)
- Where
- Poland
- Volunteers
- 202 people
- Sponsor
- Aesculap AG
Essential Hypertension
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
QGC001/1QG1 is a Phase I "first time in man" study aiming to determine the overall safety and tolerability of single ascending oral doses of QGC001 in healthy male subjects compared to placebo, as well as the pharmacokinetics of…
- Trial name
- NCT01900171
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation therapy with a lower risk of bleeding in…
- Trial name
- NCT00243178
- Testing
- clopidogrel (SR25990C)
- Where
- 32 sites in United States, Australia and 30 more
- Volunteers
- 6,706 people
- Sponsor
- Sanofi
Upper Extremity Paresis, Stroke, Chronic
Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits
This is a single-center, multiphase pilot study of 16 subjects with residual upper extremity deficits at least six months after a supratentorial ischemic or hemorrhagic stroke.
- Trial name
- NCT06288217
- Testing
- NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), Upper Limb Rehabilitation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NeuraStasis, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.